Update of evidence- and consensus-based guidelines for the treatment of juvenile idiopathic arthritis (JIA) by the German Society of Pediatric and Juvenile Rheumatic Diseases (GKJR): New perspectives on interdisciplinary care.

Autor: Oommen PT; Department of Pediatric Oncology, Hematology and Clinical Immunology, Division of Pediatric Rheumatology, University Hospital, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany. Electronic address: Prasad.Oommen@med.uni-duesseldorf.de., Strauss T; Department of Pediatrics, Medical Faculty Carl Gustav Carus, Dresden, Germany., Baltruschat K; German Rheumatism League, Bonn, Germany., Foeldvari I; Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany., Deuter C; University Hospital Tuebingen, Centre for Ophthalmology, Germany., Ganser G; St. Josef Stift Sendenhorst, Center for Pediatric and Adolescent Rheumatology, Germany., Haas JP; German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany., Hinze C; Department of Pediatric Rheumatology and Immunology, University Hospital, Münster, Germany., Holzinger D; Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany; Department of Applied Health Sciences, University of Applied Sciences Bochum, Bochum, Germany., Hospach A; Center for Pediatric Rheumatology, Clinic Stuttgart, Germany., Huppertz HI; Department of Pediatrics, Prof.-Hess Children´s Hospital, Bremen, Germany., Illhardt A; St. Josef Stift Sendenhorst, Center for Pediatric and Adolescent Rheumatology, Germany., Jung M; Fresenius University of Applied Sciences, Frankfurt/Main, Germany., Kallinich T; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany., Klein A; Department of Pediatrics, Asklepios Kinderklinik Sankt Augustin, Sankt Augustin, Germany., Minden K; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany; German Rheumatism Research Center, Berlin, Germany., Mönkemöller K; Department of Pediatrics, Kinderkrankenhaus Amsterdamer Strasse, Cologne, Germany., Mrusek S; Child and Adolescent Rheumatology, Baden-Baden, Germany., Neudorf U; Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany., Dückers G; Helios Klinikum Krefeld, Department of Pediatrics, Germany., Niehues T; Helios Klinikum Krefeld, Department of Pediatrics, Germany., Schneider M; Policlinic and Hiller Research Unit for Rheumatology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Germany., Schoof P; Private office for general pediatrics, pediatric rheumatology, pediatric neurology, Ph. Schoof und Dr. A. Müller, Cosimastrasse 106, 81927 München, Germany., Thon A; Department of Paediatric Pneumology, Allergology and Neonatology, Children's Hospital, Medical School, Hannover, Germany., Wachowsky M; Clinic Rummelsberg, Department of Orthopedics, Germany., Wagner N; RWTH Aachen, Department of Pediatrics, Germany., Bloedt S; Association of Scientific Medical Associations (AWMF), Germany., Hofer M; Unité d'immuno-allergologie et rhumatologie, Unité Romande d'Immuno-Rhumatologie Pédiatrique, Service de Pédiatrie, CHUV, 1011 Lausanne, Switzerland., Tenbrock K; RWTH Aachen, Department of Pediatrics, Germany., Schuetz C; Department of Pediatrics, Medical Faculty Carl Gustav Carus, Dresden, Germany.
Jazyk: angličtina
Zdroj: Clinical immunology (Orlando, Fla.) [Clin Immunol] 2022 Dec; Vol. 245, pp. 109143. Date of Electronic Publication: 2022 Sep 30.
DOI: 10.1016/j.clim.2022.109143
Abstrakt: Background: New therapeutic strategies for juvenile idiopathic arthritis (JIA) have evolved within the past ten years, and as a result, an update of the 2011 recommendations of the German management guidelines was initiated.
Methods: A systemic literature review was performed, overarching principles were proposed and pre-selected via an online survey followed by two multidisciplinary consensus conferences. Pharmacological and non-pharmacological treatments were discussed, statements were proposed and ultimately agreed upon by nominal group technique (NGT).
Results: 12 overarching therapeutic principles, as well as 9 recommendations on pharmacological and 5 on non-pharmacological treatments for JIA were agreed upon.
Conclusion: This report summarizes the recent update of the interdisciplinary, consensus-based German guidelines on the management of JIA. The multi- and interdisciplinary participation of all caregivers was central for this patient-focused update. With these guidelines, physicians can choose an evidence-based approach, which allows better tailored treatment in this vulnerable cohort of children and adolescents.
Competing Interests: Declaration of Competing Interest Dirk Holzinger: Novartis and Sobi (speaker fees). Christoph Deuter: research support by Affibody, Panoptes, Ursapharm; AbbVie, Alimera, Amgen, Novartis, Santen, Thea, UCB (speaker fees); consulting for Alimera. Anton Hospach: SOBI, Novartis (speaker fees). Prasad T. Oommen: Novartis (speaker fees and research support). Catharina Schuetz: Novartis (research support). Norbert Wagner: GlaxoSmithKline GmbH, Sanofi-Aventis Deutschland GmbH, RG Ärztefortbildung, Ges. für Information und Organization mbH, medupdate GmbH. Tim Niehues: UptoDate.com (authorship fees), Reimbursement of travel expenses from: EMA (European Medicines Agency), PENTA (Pediatric European Network for Treatment of AIDS), JIR (Juvenile Inflammatory Cohort). Michael Wachowsky: Biomarin Germany, Nuvasive Germany (reimbursement of travel expenses). Klaus Tenbrock: Novartis foundation, Pfizer (IIT), MBS (IIT) (research grants); Advisory Board for Novartis, Pfizer, GSK. Ariane Klein: Pfizer (speaker fees). Claas Hinze: Pfizer (reimbursement of travel expenses), Novartis (advisory board). Michael Jung: AquaFitness Akademie Hanau (consultancy). Ivan Foeldvari: Novartis, hexal, Medac, Lilly, Pfizer (advisory boards). Kirsten Minden: Pfizer, Novartis (consultancy), Abbvie, Novartis, Pfizer, Roche, Initiative for the child with rheumatism (speaker fees); Medac (honoraria). Tilmann Kallinich: Roche (speaker fees). Karen Baltruschat, Gerd Ganser, Johannes-Peter Haas, Hans-Iko Huppertz, Arnold Illhardt, Kirsten Mönkemöller, Sonja Mrusek, Ulrich Neudorf, Gregor Dückers, Matthias Schneider, Philipp Schoof, Angelika Thon, Susanne Bloedt, Michael Hofer declare no conflict of interest.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: